A comparison of immunotherapy delivery methods for allergen immunotherapy

Expert Review of Clinical Immunology

Volumn 9, Issue 5, 2013, Pages 465-475

  Klimek, Ludger ^a   Pfaar, Oliver ^a  

^a Center for Rhinology and Allergy   (Germany)

Author keywords

adjuvants; allergen specific immunotherapy; CpG motifs; epicutaneous immunotherapy; intralymphatic immunotherapy; subcutaneous immunotherapy; sublingual immunotherapy; virus like particles

Indexed keywords

ALUMINUM HYDROXIDE; AMB A 1 ANTIGEN; ANTIALLERGIC AGENT; ANTIHISTAMINIC AGENT; CORTICOSTEROID; CPG OLIGODEOXYNUCLEOTIDE; CYT 003; HOUSE DUST ALLERGEN; IMMUNOMODULATING AGENT; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MODULAR ANTIGEN TRANSPORTER FEL D 1 VACCINE; POLLEN ANTIGEN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; VIRUS LIKE PARTICLE VACCINE;

ALLERGEN IMMUNOTHERAPY; ALLERGIC RHINITIS; ALLERGY; BLOOD SAMPLING; CD4+ CD25+ T LYMPHOCYTE; COCHRANE LIBRARY; CORTICOSTEROID THERAPY; CPG ISLAND; DOSE RESPONSE; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; ECZEMA; EPIDERMIS; FOLLOW UP; HAY FEVER; HOUSE DUST ALLERGY; HUMAN; HUMORAL IMMUNITY; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATORY CELL; INTRALYMPHATIC IMMUNOTHERAPY; LYMPHOCYTE PROLIFERATION; MAST CELL; MEDICAL LITERATURE; MEDLINE; MUCOSAL IMMUNITY; NONHUMAN; PLACEBO EFFECT; POLLEN ALLERGY; PRACTICE GUIDELINE; PRICK TEST; PROTEIN MOTIF; QUALITY OF LIFE; RADIOALLERGOSORBENT TEST; RAGWEED; REVIEW; RHINOCONJUNCTIVITIS; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; TH1 CELL; TH2 CELL; VIRUS LIKE AGENT; VIRUS PARTICLE;

ALLERGENS; DESENSITIZATION, IMMUNOLOGIC; HUMANS; HYPERSENSITIVITY; INJECTIONS, SUBCUTANEOUS; SUBLINGUAL IMMUNOTHERAPY;

EID: 84877250200     PISSN: 1744666X     EISSN: 17448409     Source Type: Journal    
DOI: 10.1586/eci.13.25     Document Type: Review

References (78)

1. Asher MI, Montefort S, Björkstén B et al.; ISAAC Phase Three Study Group. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 368(9537), 733-743 (2006
2. Björkstén B, Clayton T, Ellwood P, Stewart A, Strachan D; ISAAC Phase III Study Group. Worldwide time trends for symptoms of rhinitis and conjunctivitis: Phase III of the International Study of Asthma and Allergies in Childhood. Pediatr. Allergy Immunol. 19(2), 110-124 (2008
3. Weißbuch Allergie in Deutschland. Ring J, Bachert C, Bauer CP, Czech W (Eds). Urban & Vogel, Munich, Germany (2009
4. Maurer M, Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy 62(9), 1057-1063 (2007
5. Jacobsen L, Niggemann B, Dreborg S et al.,;The PAT investigator group. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 62(8), 943-948 (2007
6. Calderon MA, Gerth van Wijk R, Eichler I et al.; European Academy of Allergy and Clinical Immunology. Perspectives on allergen-specific immunotherapy in childhood: an EAACI position statement. Pediatr. Allergy Immunol. 23(4), 300-306 (2012
7. Zuberbier T, Lotvall J. Allergies have a socioeconomic impact: a model calculation. Allergy 63(Suppl. 88), 612-621 (2008
8. von der Schulenburg JM, Greiner W, Molitor S et al. [Kosten der Asthmatherapie nach Schweregrad: eine empirische Untersuchung.] Med. Klin. (Munich) 91, S670-S676 (1996
9. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst. Rev. 1, CD001936 (2007
10. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst. Rev. 12, CD002893 (2010
11. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst. Rev. 8, CD001186 (2010
12. Kleine-Tebbe J, Bufe A, Ebner C et al.; Deutschen Gesellschaft für Allergologie und klinische Immunologie; Ärzteverbandes Deutscher Allergologen; Gesellschaft für Pädiatrische Allergologie und Umweltmedizin; Österreichischen Gesellschaft für Allergologie und Immunologie; Schweizerischen Gesellschaft für Allergologie und Immunologie. [Die spezifische Immuntherapie (Hyposensibilisierung) bei IgE-vermittelten allergischen Erkrankungen]. Allergo J. 18, 508-537 (2009
13. Calderón MA, Larenas D, Kleine-Tebbe J et al. European Academy of Allergy and Clinical Immunology task force report on 'dose-response relationship in allergen specific immunotherapy'. Allergy 66(10), 1345-1359 (2011
14. Malling HJ, Abreu-Nogueira J, Alvarez Cuesta E et al. Local immunotherapy. Allergy 53(10), 933-944 (1998
15. Zuberbier T, Bachert C, Bousquet PJ et al. GA LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 65(12),1530 (2010
16. Bousquet J, Lockey R, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. A WHO position paper. J. Allergy Clin. Immunol. 102(4 Pt 1), 558-562 (1998
17. Canonica GW, Bousquet J, Casale T et al. Sublingual immunotherapy: Wold Allergy Organization position paper 2009. Allergy 64(Suppl. 91), 1-59 (2009
18. Walker SM, Durham SR, Till SJ et al.; British Society for Allergy and Clinical Immunology. Immunotherapy for allergic rhinitis. Clin. Exp. Allergy 41(9), 1200 (2011
19. Matricardi PM, Kuna P, Panetta V, Wahn U, Narkus A. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. J. Allergy Clin. Immunol. 128(4), 791-799.e6 (2011
20. Calderón MA, Cox L, Casale TB, Moingeon P, Demoly P. Multiple-allergen and single-allergen immunotherapy strategies in polysensitized patients: looking at the published evidence. J. Allergy Clin. Immunol. 129(4), 929-934 (2012
21. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 61(2), 198-201 (2006
22. Fujita H, Soyka MB, Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. Clin. Transl. Allergy 2(1), 2 (2012
23. James LK, Shami MH, Walker SM et al. Long-term tolerance after allergen immunotherapy is accompanied by selective persistence of blocking antibodies. J. Allergy Clin. Immunol. 127, 509-516 (2011
24. Haugaard L, Dahl R, Jacobsen L. A controlled dose-response study of immunotherapy with standardized, partially purified extract of house dust mite: clinical efficacy and side effects. J. Allergy Clin. Immunol. 91(3), 709-722 (1993
25. Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J. Allergy Clin. Immunol. 120(6),1345 (2007
26. Chapman MD, Ferreira F, Villalba M et al.; CREATE consortium. The European Union CREATE project: a model for international standardization of allergy diagnostics and vaccines. J. Allergy Clin. Immunol. 122(5), 882-889.e2 (2008
27. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A; Study Group. Efficacy and safety of preseasonal-specific immunotherapy with an aluminiumadsorbed six-grass pollen allergoid. Allergy 60(6), 801-807 (2005
28. DuBuske LM, Frew AJ, Horak F et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc. 32(3), 239-247 (2011
29. Pfaar O, Urry Z, Robinson DS et al. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy 67(2), 272-279 (2012
30. Pfaar O, Robinson DS, Sager A, Emuzyte R. Immunotherapy with depigmentedpolymerized mixed tree pollen extract: a clinical trial and responder analysis. Allergy 65(12), 1614-1621 (2010
31. Zielen S, Kardos P, Madonini E. Steroidsparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J. Allergy Clin. Immunol. 126(5), 942-949 (2010
32. Riechelmann H, Schmutzhard J, van der Werf JF, Distler A, Kleinjans HA. Efficacy and safety of a glutaraldehydemodified house dust mite extract in allergic rhinitis. Am. J. Rhinol. Allergy 24(5), e104-e109 (2010
33. Durham SR, Emminger W, Kapp A et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J. Allergy Clin. Immunol. 129(3), 717-725.e5 (2012
34. Ott H, Sieber J, Brehler R et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 64(9), 1394-1401 (2009
35. Valovirta E, Berstad AK, de Blic J et al.; GAP investigators. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin. Ther. 33(10), 1537-1546 (2011
36. Horak F, Zieglmayer P, Zieglmayer R et al. Early onset of action of a 5-grass-pollen 300-IR sublingual immunotherapy tablet evaluated in an allergen challenge chamber. J. Allergy Clin. Immunol. 124(3), 471-477.e1 (2009
37. Senti G, Prinz Vavricka BM, Erdmann I et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc. Natl Acad. Sci. USA 105(46), 8-17912 (2008
38. Senti G, Graf N, Haug S et al. Epicutaneous allergen administration as a novel method of allergen-specific immunotherapy. J. Allergy Clin. Immunol. 124(5), 997-1002 (2009
39. Senti G, Crameri R, Kuster D et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only injections. J. Allergy Clin. Immunol. 129(5), 1290-1296 (2012
40. Kündig TM. Immunotherapy concepts under investigation. Allergy 66(Suppl. 95), 60-62 (2011
41. Senti G, Johansen P, Kündig TM. Intralymphatic immunotherapy: from the rationale to human applications. Curr. Top. Microbiol. Immunol. 352, 71-84 (2011
42. Senti G, von Moos S, Tay F et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: a double-blind, placebo-controlled dose escalation study. J. Allergy Clin. Immunol. 129(1), 128-135 (2012
43. von Moos S, Kündig TM, Senti G. Novel administration routes for allergen-specific immunotherapy: a review of intralymphatic and epicutaneous allergen-specific immunotherapy. Immunol. Allergy Clin. North Am. 31(2), 391-406, xi (2011
44. Senti G, von Moos S, Kündig TM. Epicutaneous allergen administration: is this the future of allergen-specific immunotherapy? Allergy 66(6), 798-809 (2011
45. Senti G, Freiburghaus AU, Kundig TM. Epicutaneous/transcutaneous allergenspecific immunotherapy: rationale and clinical trials. Curr. Opin. Allergy Clin. Immunol. 10(6), 582-586 (2010
46. Pfaar O, Böttcher I, Klimek L. Modulation of specific immunotherapy by adjuvants: immunological effects and clinical perspectives. Allergo J. 18, 261-266 (2009
47. Puggioni F, Durham SR, Francis JN. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy 60(5), 678-684 (2005
48. Stuck BA, Schneider-Gene S, Klimek L, Schäfer D, Hörmann K. Short-term immunotherapy with birch pollen allergoid plus monophosphoryl lipid A (MPL) influences cytokine production of peripheral T cells in patients with allergic rhinitis. ACI International 16, 60-64 (2004
49. Drachenberg KJ, Wheeler AW, Stuebner P, Horak F. A well-tolerated grass pollenspecific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy 56(6), 498-505 (2001
50. Allam JP, Novak N, Fuchs C et al. Characterization of dendritic cells from human oral mucosa: a new Langerhans' cell type with high constitutive FcepsilonRI expression. J. Allergy Clin. Immunol. 112(1), 141-148 (2003
51. Novak N, Bieber T, Allam JP. Immunological mechanisms of sublingual allergen-specific immunotherapy. Allergy 66(6), 733-739 (2011
52. Allam JP, Peng WM, Appel T et al. Toll-like receptor 4 ligation enforces tolerogenic properties of oral mucosal Langerhans cells. J. Allergy Clin. Immunol. 121(2), 368-374.e1 (2008
53. Pfaar O, Barth C, Jaschke C, Hörmann K, Klimek L. Sublingual allergen-specific immunotherapy adjuvanted with monophosphoryl lipid A: a Phase I/IIa study. Int. Arch. Allergy Immunol. 154(4), 336-344 (2011
54. Sledge RF. Treatment of hay-fever with alum-precipitated pollen. US Naval Med. Bulletin 36, 18 (1938
55. Rask C, Lund L, Lund G et al. An alternative allergen:adjuvant formulation potentiates the immunogenicity and reduces allergenicity of a novel subcutaneous immunotherapy product for treatment of grass-pollen allergy. Clin. Exp. Allergy 42(9), 1356-1368 (2012
56. Wilcock LK, Francis JN, Durham SR. Aluminium hydroxide down-regulates T helper 2 responses by allergen-stimulated human peripheral blood mononuclear cells. Clin. Exp. Allergy 34(9), 1373-1378 (2004
57. Frew AJ, Powell RJ, Corrigan CJ, Durham SR; UK Immunotherapy Study Group. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117(2), 319-325 (2006
58. Pfaar O, Jung K, Wolf H et al. Immunological effects and tolerability of a new fast updosed immunologically enhanced subcutaneous immunotherapy formulation with optimized allergen/adjuvant ratio. Allergy 67(5), 630-637 (2012
59. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10(11), 787-796 (2010
60. Jennings GT, Bachmann MF. The coming of age of virus-like particle vaccines. Biol. Chem. 389(5), 521-536 (2008
61. Jennings GT, Bachmann MF. Designing recombinant vaccines with viral properties: a rational approach to more effective vaccines. Curr. Mol. Med. 7(2), 143-155 (2007
62. Yewdell JW. Designing CD8+ T cell vaccines: it's not rocket science (yet). Curr. Opin. Immunol. 22(3), 402-410 (2010
63. Tewalt EF, Grant JM, Granger EL et al. Viral sequestration of antigen subverts cross presentation to CD8+ T cells. PLoS Pathog. 5(5), e1000457 (2009
64. Klinman DM. Immunotherapeutic uses of CpG oligodeoxynucleotides. Nat. Rev. Immunol. 4(4), 249-258 (2004
65. Bode C, Zhao G, Steinhagen F, Kinjo T, Klinman DM. CpG DNA as a vaccine adjuvant. Expert Rev. Vaccines 10(4), 499-511 (2011
66. Garland SM, Hernandez-Avila M, Wheeler CM et al.; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356(19), 1928-1943 (2007
67. Paavonen J, Jenkins D, Bosch FX et al.; HPV PATRICIA study group. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and in young women: an interim analysis of a Phase III double-blind, randomised controlled trial. Lancet 369(9580), 2170 (2007
68. Kündig TM, Senti G, Schnetzler G et al. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J. Allergy Clin. Immunol. 117(6), 1476 (2006
69. Creticos PS, Schroeder JT, Hamilton RG et al.; Immune Tolerance Network Group. Immunotherapy with a ragweed-Toll-like receptor 9 agonist vaccine for allergic rhinitis. N. Engl. J. Med. 355(14), 1455 (2006
70. Senti G, Johansen P, Haug S et al. Use of A-type CpG oligodeoxynucleotides as an adjuvant in allergen-specific immunotherapy in humans: a Phase I/IIa clinical trial. Clin. Exp. Allergy 39(4), 562-570 (2009
71. Stelmach I, Smejda K, Jerzynska J et al. Decreased markers of atopy in children with presumed early exposure to allergens, unhygienic conditions, and infections. Ann. Allergy Asthma Immunol. 99(2), 170-177 (2007
72. Braun-Fahrländer C, Riedler J, Herz U et al.; Allergy and Endotoxin Study Team. Environmental exposure to endotoxin and its relation to asthma in school-age children. N. Engl. J. Med. 347(12), 869-877 (2002
73. Riedler J, Braun-Fahrländer C, Eder W et al.; ALEX Study Team. Exposure to farming in early life and development of asthma and allergy: a cross-sectional survey. Lancet 358(9288), 1129-1133 (2001
74. Klimek L, Willers J, Hammann-Haenni A et al. Assessment of clinical efficacy of CYT003-QbG10 in patients with allergic rhinoconjunctivitis: a Phase IIb study. Clin. Exp. Allergy 41(9), 1305-1312 (2011
75. FORSA Umfrage 2012. www.derma.de/fileadmin/eingang/ FORSA-Allergien.de
76. Guideline on allergen products: production and quality issues. Committee for Medicinal Products for Human Use. www.ema.europa.eu/docs/en-GB/ document-library/Scientific-guideline//09/WC500003333.pdf
77. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. Committee for Medicinal Products for Human Use. www.emea.europa.eu/docs/en-GB/ document-library/ Scientific-guideline//09/WC500003605.pdf
78. Paul-Ehrlich-Institut. List of approved allergen therapies. www.pei.de/cln-236/nn-154892/DE/arzneimittel/allergene/therapieallergene/ therapieallergene-node.html?-nnn=true